Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion.
First-time abciximab administration was associated with acute profound thrombocytopenia in 4 of 575 consecutive patients. Therapy with platelet transfusion, but not intravenous immunoglobulin, was associated with a rapid and sustained increment in circulating platelet count and clinical hemostasis.
Kereiakes
D J
DJ
Department of Cardiology, University of Cincinnati College of Medicine, Ohio, USA.
Essell
J H
JH
Abbottsmith
C W
CW
Broderick
T M
TM
Runyon
J P
JP
D000077284:Abciximab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D007074:Immunoglobulin G / Q000008:administration & dosage; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D010976:Platelet Count; D017713:Platelet Transfusion; D013921:Thrombocytopenia / Q000209:etiology* / Q000628:therapy
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab